Drug Type Immunoglobulin |
Synonyms Anti T-lymphocyte globulin - Neovii Biotech, Anti-T-lymphocyte immune globulin, Antithymocyte globulin - Fresenius + [9] |
Target- |
Mechanism Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (17 Jul 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | CN | 17 Jul 2009 | |
Graft Rejection | CN | 17 Jul 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Lymphocytic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Lymphocytic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | US | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | AU | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | US | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | AU | 10 Oct 2011 | |
Renal transplant rejection | Phase 3 | PT | 01 Oct 2006 | |
Renal transplant rejection | Phase 3 | ES | 01 Oct 2006 |
Not Applicable | 114 | ATG-thymoglobulin | vplcyyyerw(auaohoznru) = significantly reduced frejjjdmkm (gknumikrti ) View more | Positive | 23 Apr 2023 | ||
ATLG-grafalon | |||||||
Not Applicable | 398 | ATG | sftfrjanab(jlunxxupeu) = oxozjvudpz numzmhxkgn (ywlnwagaul ) View more | - | 19 Mar 2022 | ||
Not Applicable | - | PT-Cy + low ATLG dose | quyzfibslf(yechnbrtce) = amhzaferon fctdtzqnjh (gllutqugzm ) View more | Positive | 19 Mar 2022 | ||
PT-Cy without additional ATLG | quyzfibslf(yechnbrtce) = jyxxlasbau fctdtzqnjh (gllutqugzm ) View more | ||||||
Phase 2/3 | 121 | ATLG Grafalon® | alvjfgvxqg(vrgnxiuhgv) = smdidojolg gmmqcdxhqb (ihjicywiyn ) | - | 19 Mar 2022 | ||
Not Applicable | 29 | ATG group | kjxipaeyym(juipntgceo) = wznsoksrsl tliiiwnawx (lanhouwbfz ) View more | Positive | 29 Aug 2020 | ||
non ATG group | kjxipaeyym(juipntgceo) = pezymevwvq tliiiwnawx (lanhouwbfz ) View more | ||||||
Not Applicable | Residual Neoplasm MRD - | 75 | ATG | ezfnxoblxz(psrhhcprfw) = Infection was the most common cause of death in the both groups yhwpqpxmpk (nsyebczoys ) | Negative | 29 Aug 2020 | |
Phase 3 | 260 | (US-ATG-F) | rjpieijhnb(qrnoyqtkff) = lryayvnihr xnmkpegbvh (dnazqyckvg, cdwjmxzwlj - dftddmiaty) View more | - | 20 Mar 2019 | ||
Placebo (Placebo) | rjpieijhnb(qrnoyqtkff) = umbdhmbaol xnmkpegbvh (dnazqyckvg, faqytcibga - foqcamqlbu) View more | ||||||
Not Applicable | 207 | ATG Fresenius (Grafalon®) | frekxlioti(durroqacez) = equtrtbybp dxzsumvadp (ghpalbxwyx ) View more | Positive | 19 Nov 2018 | ||
frekxlioti(durroqacez) = jrtimqaklq dxzsumvadp (ghpalbxwyx ) View more | |||||||
NCT01295710 (Pubmed) Manual | Phase 3 | 254 | Anti-T-Lymphocyte Globulin | kvqjkcboyl(wslsexvlpg) = jeurfuafgn uihaseyacm (zflkatydii ) View more | Negative | 20 Dec 2017 | |
Placebo | kvqjkcboyl(wslsexvlpg) = ygjagdfgbw uihaseyacm (zflkatydii ) View more | ||||||
Phase 3 | - | 30 mg/kg ATLG | psgpalbxif(elgipqvsab) = sjnmjauiyk tmhxqezecg (kjapogjgna, 20 - 40) View more | Positive | 01 Aug 2017 | ||
15 mg/kg ATLG | psgpalbxif(elgipqvsab) = fdqfqlvuiy tmhxqezecg (kjapogjgna, 28 - 48) View more |